Abstract:Drug-induced blockade of the human ether-à-go-go-related gene (hERG) channel is today considered the main cause of cardiotoxicity in postmarketing surveillance. Hence, several ligand-based approaches were developed in the last years and are currently employed in the early stages of a drug discovery process for in silico cardiac safety assessment of drug candidates. Herein, we present the first structure-based classifiers able to discern hERG binders from nonbinders. LASSO regularized support vector machines were applied to integrate docking scores and protein–ligand interaction fingerprints. A total of 396 models were trained and validated based on: (i) high-quality experimental bioactivity information returned by 8337 curated compounds extracted from ChEMBL (version 25) and (ii) structural predictor data. Molecular docking simulations were performed using GLIDE and GOLD software programs and four different hERG structural models, namely, the recently published structures obtained by cryoelectron microscopy (PDB codes: 5VA1 and 7CN1) and two published homology models selected for comparison. Interestingly, some classifiers return performances comparable to ligand-based models in terms of area under the ROC curve (AUCMAX = 0.86 ± 0.01) and negative predictive values (NPVMAX = 0.81 ± 0.01), thus putting forward the herein proposed computational workflow as a valuable tool for predicting hERG-related cardiotoxicity without the limitations of ligand-based models, typically affected by low interpretability and a limited applicability domain. From a methodological point of view, our study represents the first example of a successful integration of docking scores and protein–ligand interaction fingerprints (IFs) through a support vector machine (SVM) LASSO regularized strategy. Finally, the study highlights the importance of using hERG structural models accounting for ligand-induced fit effects and allowed us to select the best-performing protein conformation (made available in the Supporting Information, SI) to be employed for a reliable structure-based prediction of hERG-related cardiotoxicity.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jcim.1c00744.Top views of the BS of all of the employed protein models and the number of active and inactive compounds as a consequence of the selected activity and inactivity thresholds (Figures S1 and S2 and Tables S1) (PDF)Kolmogorov–Smirnov test p-values summarizing the difference in docking score distributions between hERG binders and nonbinders, the SE and SP of all of the developed models, the BS volumes (Å3) of all of the used hERG models, and the interactions responsible for a lower IC50 based on the KS test performed on the IFs returned by all of the considered protein models (Tables S2–S6) (PDF)List of the compounds belonging to the hERG-DB, including SMILES strings and corresponding IC50 values (XLSX)Results of the performed docking simulations including docking scores and molecular interaction fingerprints (ZIP)Results of the performed docking simulations including molecular interaction fingerprints (ZIP)5VA1-IFD-1, 5VA1-IFD-2, 5VA1-IFD-3, 5VA1-IFD-4, and 5VA1-IFD-5 conformations as. pdb files (ZIP)This article has not yet been cited by other publications.

Experimentally Validated Modeling of Dynamic Drug-HERG Channel Interactions Reproducing the Binding Mechanisms and its Importance in Action Potential Duration.

Automated Tight Seal Electrophysiology for Assessing the Potential Herg Liability of Pharmaceutical Compounds

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Optimising experimental designs for model selection of ion channel drug binding mechanisms

Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia

In Silico Human Cardiomyocyte Action Potential Modeling: Exploring Ion Channel Input Combinations

Structural modeling of hERG channel-drug interactions using Rosetta

A Comprehensive Cardiotoxicity Assay by Combining High-Throughput Multiple Ion Channel Screening with Human Cardiomyocyte-Based Action Potential Validation

Prediction of hERG inhibition of drug discovery compounds using biomimetic HPLC measurements

Virtual screening of DrugBank database for hERG blockers using topological Laplacian-assisted AI models

Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study

Calibration of an in‐silico Human Ventricular Action Potential Model to Detect Proarrhythmic Liabilities

In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment

Improved higher resolution cryo-EM structures reveal the binding modes of hERG channel inhibitors

Temperature Effects on Kinetics of KV11.1 Drug Block Have Important Consequences for In Silico Proarrhythmic Risk Prediction

Phenomenological analysis of simple ion channel block in large populations of uncoupled cardiomyocytes

Cardiomyocyte electrical-mechanical synchronized model for high-content, dose-quantitative and time-dependent drug assessment

Rate-dependent effects of lidocaine on cardiac dynamics: Development and analysis of a low-dimensional drug-channel interaction model

Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model